{"id":"rzv","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Myalgia"},{"rate":"40-45","effect":"Fatigue"},{"rate":"35-40","effect":"Headache"},{"rate":"70-80","effect":"Injection site pain"},{"rate":"35-45","effect":"Injection site erythema"},{"rate":"25-35","effect":"Injection site swelling"},{"rate":"10-15","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RZV contains recombinant varicella-zoster virus (VZV) glycoprotein E antigen combined with an AS01B adjuvant system that enhances immune response. The vaccine works by priming both cellular and humoral immunity against VZV, reducing the risk of herpes zoster reactivation and post-herpetic neuralgia in vaccinated individuals.","oneSentence":"RZV is a recombinant zoster vaccine that stimulates the immune system to prevent herpes zoster (shingles) infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:26.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"},{"name":"Prevention of herpes zoster in immunocompromised adults aged 18 years and older"}]},"trialDetails":[{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT07321808","phase":"","title":"Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-05-16","conditions":"Immunocompromised Patients","enrollment":300},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT06890416","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-04","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":526},{"nctId":"NCT05575830","phase":"PHASE4","title":"Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Calmy Alexandra","startDate":"2022-12-14","conditions":"RZV Vaccine (Shingrix ®)","enrollment":225},{"nctId":"NCT04403139","phase":"PHASE4","title":"VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2022-04-27","conditions":"Varicella Zoster Virus Infection","enrollment":50},{"nctId":"NCT04869982","phase":"PHASE4","title":"Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-14","conditions":"Herpes Zoster","enrollment":6138},{"nctId":"NCT04169009","phase":"PHASE4","title":"Persistence of Protection by Shingrix","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-07-28","conditions":"Herpes Zoster","enrollment":105},{"nctId":"NCT06224270","phase":"PHASE4","title":"Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2024-10","conditions":"Inflammatory Bowel Diseases, IBD","enrollment":""},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT05596526","phase":"PHASE4","title":"Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients","status":"RECRUITING","sponsor":"Prof Patrice Lalive","startDate":"2022-12-01","conditions":"Shingles, Zoster","enrollment":100},{"nctId":"NCT05371080","phase":"PHASE3","title":"A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-08-10","conditions":"Herpes Zoster","enrollment":3038},{"nctId":"NCT05705180","phase":"","title":"The Influence of Trained Immunity in COVID-19 Vaccinated Individuals","status":"UNKNOWN","sponsor":"Wuerzburg University Hospital","startDate":"2022-12-01","conditions":"Zoster Varicella, Vaccination; Infection","enrollment":600},{"nctId":"NCT04516408","phase":"NA","title":"Recombinant Zoster Vaccine in Stable SLE Patients","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-04-20","conditions":"Herpes Zoster, Recombinant Zoster Vaccine, Systemic Lupus Erythematosus","enrollment":464}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"RZV","genericName":"RZV","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"RZV is a recombinant zoster vaccine that stimulates the immune system to prevent herpes zoster (shingles) infection. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults aged 18 years and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}